GlassScriptPhysician profile
John D Abdulian
NPI 1437114113
$11,106.71
in general payments reported to CMS, 2019-2025
37 companies · $2,632 in 2025
The $2,632 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $102 · 2021: $816 · 2022: $2,129 · 2023: $1,683 · 2024: $3,057 · 2025: $2,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,372.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,235.61 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Boston Scientific Corporation | $1,640.83 | 2019-2025 | Axios, X-Tack Endoscopic Helix Tacking System, General - Hemostasis |
| Janssen Biotech, INC. | $1,518.10 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,138.11 | 2019-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $531.82 | 2024-2025 | Vowst |
| Pfizer INC. | $316.50 | 2019-2025 | |
| Celgene Corporation | $282.94 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $263.13 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $242.36 | 2021-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $236.27 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $201.54 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $141.21 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $122.08 | 2024 | |
| Ardelyx, INC. | $106.15 | 2024-2025 | Ibsrela |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $97.46 | 2022-2025 | |
| Cook Medical LLC | $96.83 | 2025 | Echotip Insight |
| Braintree Laboratories, INC. | $86.49 | 2019-2023 | Sutab |
| Lilly USA, LLC | $83.22 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $74.65 | 2020-2025 | Linzess |
| Daiichi Sankyo INC. | $65.70 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $52.22 | 2019-2022 | |
| Allergan, INC. | $48.92 | 2019 | |
| Nestle Healthcare Nutrition INC. | $45.39 | 2021-2023 | |
| Qol Medical, LLC | $44.42 | 2022-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $42.01 | 2020-2022 | |
| Micro-Tech Endoscopy USA, INC. | $35.98 | 2023-2025 | Lockado, Riteclip |
| Orphalan INC | $29.83 | 2025 | Cuvrior |
| Merck Sharp & Dohme LLC | $29.04 | 2023 | Dificid |
| Organon LLC | $26.97 | 2024 | |
| Fresenius Kabi USA, LLC | $26.41 | 2024 | Idacio |
| Redhill Biopharma INC. | $22.01 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.95 | 2024 | Crysvita |
| Shionogi INC | $20.75 | 2019 | |
| Albireo Pharma, INC. | $19.72 | 2024 | Iqirvo |
| Shield Therapeutics INC | $19.33 | 2023 | Accrufer |
| Shire North American Group INC | $16.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abdulian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.